Milestone Achievement and Market Context
On 07 April 2026, Integrated Proteins Ltd's stock price surged to Rs 78.73, marking its highest-ever closing level. This peak surpasses the previous 52-week high of Rs 77.19 by 1.57%, underscoring the company’s strong market presence. Despite opening with a gap down of 2% and touching an intraday low of Rs 75.65, the stock managed to close with a 2.00% gain for the day, outperforming the Sensex’s 0.62% rise. The stock’s trading range remained narrow at Rs 0.35, indicating a consolidation phase near this historic peak.
Performance Relative to Sector and Market Benchmarks
Integrated Proteins operates within the edible oil industry, a sector that has seen mixed movements recently. While the solvent extraction segment gained 3.24% on the day, Integrated Proteins underperformed its sector by 4.72%. However, the stock’s longer-term performance paints a more compelling picture. Over the past month, it has surged by 73.22%, vastly outpacing the Sensex’s decline of 5.52%. The three-month return is even more striking at 141.35%, compared to the Sensex’s negative 12.24%. Year-to-date, the stock has appreciated by 128.87%, while the benchmark index has fallen 12.50%. Over a decade, Integrated Proteins has delivered an extraordinary 3,578.97% gain, dwarfing the Sensex’s 202.06% rise.
Technical Indicators and Trend Analysis
The stock’s technical profile remains predominantly bullish. Since 27 March 2026, the trend shifted from sideways to bullish at a price of Rs 71.33. Key technical indicators such as the MACD and Bollinger Bands signal bullish momentum on both weekly and monthly charts. Moving averages across 5, 20, 50, 100, and 200 days confirm the upward trajectory, with the stock trading comfortably above these levels. The Relative Strength Index (RSI) shows a bearish signal on the weekly scale but no signal monthly, suggesting some short-term caution amid the broader positive trend. Support levels are well established at the 52-week low of Rs 20.71, while resistance points include the 20-day moving average area at Rs 59.84 and the 100-day moving average at Rs 38.09, both of which have been decisively surpassed.
Valuation Metrics Reflect Elevated Market Expectations
Integrated Proteins’ valuation multiples as of 07 April 2026 indicate a premium pricing reflective of its growth trajectory. The price-to-earnings (P/E) ratio stands at a high 438 times trailing twelve months earnings, while the price-to-book value (P/BV) is 7.10 times. Enterprise value multiples such as EV/EBITDA and EV/EBIT both register at 144.45 times, signalling elevated market expectations. The EV/Sales ratio is 5.62 times, and EV/Capital Employed is 7.10 times. Dividend metrics are not applicable, with no dividend yield or payout recorded. These valuation levels suggest investors are pricing in the company’s strong sales growth and market position despite modest earnings and profitability metrics.
Quality and Financial Performance Overview
Integrated Proteins is classified as a micro-cap company with a Mojo Score of 44.0 and a current Mojo Grade of Sell, upgraded from Strong Sell on 27 March 2026. The company’s quality assessment indicates a below-average overall grade, reflecting challenges in long-term financial performance. Management risk and capital structure are rated below average, while growth is considered average. The company has demonstrated a robust 5-year sales growth of 92.87%, though EBIT growth over the same period is more modest at 7.26%. Leverage remains low with an average debt to EBITDA ratio of 0.46 and negligible net debt to equity. The average return on capital employed (ROCE) and return on equity (ROE) are weak at -5.14% and 1.51% respectively, highlighting limited profitability despite strong top-line expansion.
Delivery Volumes and Market Activity
Recent delivery volumes show a significant increase, with a 1-month delivery change of 68.45% and a 1-day delivery change of 55.14% compared to the 5-day average. On 06 April 2026, the volume stood at 1.17 lakh shares, representing 100% of total traded volume, though this is below the 5-day average volume of 2.6 lakh shares. This heightened delivery activity suggests increased investor participation in the stock’s recent rally.
Stock Price Journey and Historical Context
The stock’s journey to its all-time high has been marked by sustained gains over multiple time horizons. The 1-year performance of 63.61% and the 3-year return of 542.69% significantly outperform the Sensex’s 1.95% and 24.62% respectively. The absence of any recorded 5-year return data contrasts with the exceptional 10-year growth, underscoring the company’s long-term value creation. The current price is 36.33% above the previous 52-week high of Rs 57.75 and a substantial 280.15% above the 52-week low of Rs 20.71, illustrating a strong recovery and expansion phase.
Summary of Key Metrics at All-Time High
As of 07 April 2026, Integrated Proteins Ltd’s stock price stands at Rs 78.73, with a day change of 2.00%. The stock trades above all major moving averages, confirming a bullish technical stance. Valuation multiples remain elevated, reflecting market optimism. The company’s quality metrics highlight areas for improvement, particularly in profitability and management risk, while sales growth remains a standout strength. Delivery volumes have increased notably, supporting the price momentum. The stock’s performance relative to the Sensex and sector indices over various periods underscores its exceptional growth trajectory.
Conclusion
Integrated Proteins Ltd’s attainment of an all-time high price represents a significant milestone in its market journey. The stock’s strong performance across multiple time frames, supported by bullish technical indicators and robust sales growth, has propelled it to this historic level. While valuation multiples are elevated and quality metrics suggest room for improvement, the company’s ability to sustain this peak will depend on maintaining its growth momentum and addressing underlying financial challenges. This achievement marks a noteworthy chapter in Integrated Proteins’ evolution within the edible oil sector.
